Sorry, you need to enable JavaScript to visit this website.
Skip to main content

The asia-pacific cro

Take advantage of the world's fastest growing clinical trials region.

We look forward to discussing
your research strategy.

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

Accelerating clinical trials with faster site selection and patient recruitment

Challenges

Sponsors in Europe and North America are facing increased challenges around participant recruitment and retention, lengthy timeframes and relatively high costs.

Asia-Pacific has become a key location for clinical trials, driven by its large patient population, scale of medical facilities, government support for clinical trials, strategic importance of Asian economies as end consumer markets, lower trial costs, and high-quality standards.

Novotech and PPC Group formed a strategic partnership in 2019 creating the largest biotech CRO specialist in the Asia-Pacific region. The partnership brings together approximately 1,200 staff to meet the growing biotech demand in the region.

 

A multi-award winning regional contract research organization (CRO)

Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific Region.

Where We operate

  • Asia
  • North America
  • Oceania

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators 
     
India

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost

United States of America

 

Novotech has two customer facing offices
on both the East Coast and West Coast.

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Our Company

"Novotech is a great place to build a career. We are very focused on providing motivating work, having an inclusive culture, a flexible workplace, and very high levels of transparency with our people.  I am absolutely committed to Novotech being a leader in gender equality which is a key part of our workplace philosophy."

- Dr. John Moller

Chief Executive Officer, Novotech CRO

Our Latest Reports

Upcoming Events

Biocom Annual Global Life Science Partnering
25 Feb 20 to 27 Feb 20
La Jolla, USA
AustChamKorea AGM
26 Feb 20
Seoul,Korea
OCT West Coast
03 Mar 20 to 04 Mar 20
Burlingame, USA
NSW Women in Life Sciences Luncheon
06 Mar 20
Sydney, Australia
Bio Asia
10 Mar 20 to 11 Mar 20
Tokyo, Japan
OCT Israel
17 Mar 20 to 18 Mar 20
Tel Aviv, Israel